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Abstract
Objective-To compare the efficacy and
safety of oral acyclovir (400 mg twice
daily) with oral isoprinosine (500 mg
twice daily) in the suppression of recur-
rent genital herpes.
Design-Double-blind, double-dummy,
randomised, controlled, parallel group
trial.
Setting-13 centres in UK, Belgium and
Germany.
Subjects-127 immunocompetent patients
with frequently recurring genital herpes.
Main outcome measures-Proportions of
patients reporting recurrences, recur-
rence frequency, and mean duration of
lesions during breakthrough recurrences
in each treatment group during a 6 month
treatment period; time to first recurrence
during treatment and follow-up after
treatment cessation.
Results-During treatment, acyclovir
recipients showed significant differences
(p < 0.05) when compared with isoprino-
sine recipients in terms ofa lower propor-
tion reporting recurrences (31% vs 96%),
a reduced mean number of reported
recurrences per patient (0.6 vs 3.6), a
shorter mean duration of breakthrough
lesions (6.4 days vs 8.2 days), and a longer
mean time (standard error) to first recur-
rence (143.7 (9.1) days vs 40.5 (5.4) days.
The mean time to first recurrence after
treatment cessation did not differ between
the two groups. As compared with placebo
recipients, isoprinosine treated patients
had an increased recurrence frequency
(3.6 vs 2.5) during treatment, and a
shorter time to first recurrence after
treatment cessation. All treatments were
well tolerated without serious adverse
events or toxicity.
Conclusions-Acyclovir is very effective
in suppressing recurrent genital herpes
and is clearly superior to isoprinosine
which is not clinically useful in the dosage
studied.
Introduction
Recurrent genital herpes (RGH) infections are
becoming increasingly common and are often
a source of considerable physical discomfort
and emotional disturbance in affected patients.
Numerous different treatments have been sug-
gested for the management of patients with
genital herpes; these include antiviral drugs
and immuno-modulators.' 2 The majority of
these preparations have been shown in clinical
trials to be ineffective. However, both acyclovir
and inosine pranobex/isoprinosine have been
reported to reduce the frequency of recur-
rences in separate controlled trials.3"'l
The aim of this study was to compare the
efficacy and tolerance of these oral agents in




This was a multi-centre, double-blind, double-
dummy, randomised, controlled, parallel
group trial in patients with a history of RGH.
The study was approved by the Ethical
Committee of each hospital prior to patient
entry.
Patient selection and exclusion
Patients aged 16 years or more with a known
history of frequent attacks of recurrent herpes
genitalis (six or more per year) were invited to
participate. A culture positive recurrence dur-
ing the observation period was necessary for
inclusion in the study. Women who were not
adequately protected against pregnancy, and
patients of either sex with known HIV infec-
tion, other causes of immunosuppression, a
history of gastrointestinal malabsorption, renal
disease with a creatinine clearance below
50 ml/min, gout or hyperuricaemia, or severe
atopic eczema were excluded. All patients were
informed of the experimental nature of the
treatment and were asked to give their consent
to participate, prior to entering the study.
Patient management
Eligible patients were initially observed with-
out treatment for 8 weeks. During this obser-
vation period, they were required to complete
daily diary cards detailing symptoms and signs
of recurrences. They were asked to return to
the clinic either at the first signs of a sub-
sequent recurrence, when separate swabs were
taken from external and internal lesions pres-
ent, or otherwise every 4 weeks when diary
cards were checked and replaced.
They then progressed to the treatment
period which continued for 24 weeks. Treat-
ment was commenced 7 days after the start of
the first recurrence subsequent to the observa-
tion period. Each patient was given two bottles
of tablets and instructed to take one tablet
from each twice daily. They were randomly
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Table 1 Demographic data at study entry
Placebo Acyclovir Isoprinosine
(N = 25) (N = 53) (N = 49)
Males (%) 60 69 59
Females (%) 40 31 41
Age (Mean years, SD) 33.7, 10-9 33-5, 8-3 35-7, 10-4
History of genital herpes, no episodes preceding year
(Mean, SD) 11-7, 7-3 10-9, 5.0 10-8, 6-4
Average Duration (Mean days, SD) 9-2, 2-7 8-6, 3-6 8-7, 3-9
Symptom Severity (Mean score) 1-8 1-8 2-0
(1) active acyclovir* (400 mg twice daily) and
isoprinosine placebo; (2) active isoprinosinet
(500 mg twice daily) and acyclovir placebo;
(3) both isoprinosine placebo and acyclovir
placebo.
The protocoled ratio of patients assigned to
the acyclovir, isoprinosine, and placebo treat-
ment groups were 2:2:1 respectively. The code
for allocating patients to each of the treatment
groups was prepared using a computer gen-
erated randomisation table by the Department
of Clinical Statistics and Data Handling, Well-
come Research Laboratories, Beckenham,
Kent.
Patients were followed-up for a further 24
weeks after cessation of treatment ("follow up
period") to assess their post-treatment recur-
rence pattern. The first two recurrences were
not treated, thereafter the patients were issued
with acyclovir cream.
Measurements and evaluations
Throughout treatment and subsequent follow
up, patients reported compliance and symp-
toms on diary cards. They were observed
monthly and during recurrences of infection
for clinical and safety assessments. Whenever
possible, the patient suspicion of recurrence
was clinically confirmed. Concomitant medi-
cation was not restricted, but was recorded in
each patient's case record form.
Blood samples were taken for routine hae-
matological and biochemical measurements
immediately before treatment started, once
every eight weeks during the treatment period,
and at the first visit after treatment was
discontinued. Haematological parameters
measured included haemoglobin, haematocrit,
red blood cell count, white blood cell count,
neutrophil, lymphocyte and platelet counts.
Biochemical parameters measured included
serum creatinine concentration, urea and uric
acid concentrations and aspartate transami-
nase as an indicator of liver function.
All adverse events were recorded and rated
by the investigator for severity and for the
possibility of an association with the study
drug(s) at each visit.
Data analysis
For all analyses, the data were pooled over
centres because of the low patient numbers in
some centres.
Summary statistics to describe the age, sex,
*Acyclovir tablets (400 mg) with matching placebo were made,
packed and labelled by the Wellcome Foundation Limited at
Dartford, UK.
tIsoprinosine tablets (500 mg) were obtained from a whole-
saler. The tablets were made, packed and labelled by Edwin
Burgess Limited, Aylesbury, UK. Matching inerts were made
by the Wellcome Foundation at Dartford, UK.
number and severity of HSV episodes were
calculated for the patients in each of the three
treatment groups. The efficacy and laboratory
data were dual entered and edited into a
computer database system for analysis. All the
summary statistics were produced using the
SAS statistical package. The Kaplan-Meier




A total of 127 patients were entered into the
study. Ten patients did not experience a recur-
rence during the observation period. One
withdrew from the study and nine continued in
the treatment and follow up periods. Of these
five received acyclovir, two received isoprino-
sine and two received placebo. Thus, a total of
126 patients were included for the efficacy
analysis.
Demographic details and baseline characteristics
Demographic details and baseline character-
istics of patients at entry are summarised in
table 1. The three treatment groups were
comparable for mean age, sex ratio, and
preceding history of recurrent genital herpes.
Number ofpatients reporting recurrent lesions
(table 2)
During two months observation, the percen-
tages of patients reporting one or more recur-
rences were 91% in the acyclovir group, 96%
in the isoprinosine group and 92% in the
placebo group. During the 6 month treatment
period, however, the percentage of patients
reporting one or more recurrences was 31% in
the acyclovir group, 96% in the isoprinosine
group and 79% in the placebo group. The
percentage of patients in the acyclovir group
was significantly lower (p < 0.05) than the
percentages in either the placebo group or the
isoprinosine group.
During follow up, the percentage of patients
reporting one or more recurrences was 82% in
the acyclovir group, 69% in the isoprinosine
group and 50% in the placebo group. The
difference between the percentages in the
acyclovir and isoprinosine groups were not
statistically significant, however there were
significantly fewer recurrences amongst
placebo treated patients (p < 005).
Number of reported recurrent episodes
The mean number of reported recurrent infec-
tions per patient during the 2 months observa-
tion period was similar in all three treatment
groups (table 2).
During treatment, the mean number of
reported recurrences per patient was 0.6 in the
acyclovir group, 3.6 in the isoprinosine group
and 2.5 in the placebo group. These mean
values were significantly different (p < 0.05)
between all pairs of treatments. In the acyclovir
group only 3.6% of patients had three or more
reported recurrences compared with 59.2% in
the isoprinosine group and 41.7% in the
placebo group.
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Table 2 Frequency of recurrences
Treatment group 95% confidence intervals for differences
Placebo (N = 24) Acyclovir (N = 53) Isoprinosine (N = 49) A-P I-P A-I
No. (%) patients reporting a recurrence
Observation 22-0 (92%) 50-0 (91%) 47-0 (96%)
Treatment 19-0 (79%) 17-0 (31%) 47.0 (96%) (-68-4%, -27.6%)* ( 19%, 34 2%) (-78-4%, -51-6%)*
Follow-up 12-0 (50%) 45.0 (82%) 34 0 (69%) ( 9-6%, 54.4%)* (-4-8%, 42 8%)* ( -3-5%, 29.5%)
Mean no. recurrences per patients
Observation 2-13 2-29 2-76
Treatment 2-54 0-64 3-57 (-2-90, -0-91)* ( 001, 2.04)* (-373, -2-14)*
Follow-up 1-67 2-82 2-92 (-011, 2-41) (-004,253) (-111,092)
Mean time (days) to first recurrence
Treatmentt 56.2 (10-9) 143-7 (9.1) 40.5 (5.4) ( 59 7, 1152)* (-39.5, 8.0) ( 82-5, 123-9)*
Follow-up* 244-7 (10-6) 239-5 (8.0) 240-4 (9.8) (-31-3, 20.8) (-32-7, 24 0) (-25-7, 23.9)
Treatment to study ends 88-1 (22.6) 188-2 (14-3) 40.5 (5.4) ( 47.7, 152-5)* (-93-1, -2-1)* ( 117-7, 177-6)*
*Significant at 5% level.
tTo first recurrence during treatment.
*To first recurrence in follow-up (from start of treatment period).
STo first recurrence at any time during treatment or follow-up.
Table 3 Duration of recurrences and symptoms
Treatment group 95% confidence intervals for differences
Placebo (N = 24) Acyclovir (N = 53) Isoprinosine (N = 49) A-P I-P A-I
Mean duration (days) of recurrences
Observation 8-7 8-2 7-7
Treatment 7-7 6 4 8-2 (-315, 0.47) (-0-82, 1-72) (-3-37, -0-21)*
Follow-up 7-4 7-6 7-2 (-151, 193) (-198, 1-48) (-0-66, 1-58)
Mean duration (days) with symptomslerythema
Observation 3-5 3.9 3-8
Treatment 7-8 10-4 10-2 (-635, 11-48) (-6-42, 11-21) (-6-90, 7 23)
Follow-up 10-7 8-8 8-6 (-13-40, 9.68) (-13-86, 9 82) (-7.97, 8 30)
*Significant at 5% level.
During follow up, the mean number of
reported recurrences per patient was 2.8 in the
acyclovir group, 2-9 in the isoprinosine group
and 1.7 in the placebo group. There were no
statistically significant differences between any
pairs of treatment groups.
Number of days from treatment onset to first
recurrence
The mean time to the first recurrence from the
start of treatment was estimated for each
treatment group. This was significantly longer
(p < 0.05) for acyclovir recipients (143.7
days), than for isoprinosine recipients (40.5
days) or for placebo recipients (56'2 days)
(table 2). The mean time to the first recurrence
in the post-treatment period, measured from
the start of the treatment period was virtually
the same in all three treatment groups.
The distributions of the Kaplan-Meier esti-
mates of proportions of recurrence-free








0 W0 100 150 200
DAY FROM START OF TREATMENT
Figure 1 Time to 1st recurrent episode during treatment andj
study.
ences between the acyclovir and placebo
groups (p = 0.0001) and between the acyclovir
and isoprinosine groups (p = 0.0001) (fig 1).
There was no significant difference between
the placebo and isoprinosine groups. During
follow up, there was no statistical evidence to
suggest that the distributions of Kaplan-Meier
estimates of proportions of recurrence free
patients differed between treatment groups (fig
2).
Mean duration of recurrences
During both the observation and post-treat-
ment periods, there were no differences
between the treatment groups with respect to
the mean duration of recurrences (table 3).
However, during treatment, the mean duration
for the acyclovir group (6.4 days) was sig-
nificantly shorter (p < 0'05), than for the
isoprinosine group (8.2 days).
Mean duration of symptomslerythema
The mean duration of symptoms/erythema
(that is, the total number of days per patient,
with symptoms and/or erythema, but without
lesions) was calculated for each treatment
group. The 95% confidence intervals for differ-
ences between the means included zero and
gave no evidence for any statistically significant
differences between any pairs of treatment
during the treatment or follow-up periods.
Adverse events
In general, all treatments were extremely well
tolerated with only six patients reporting 11
. adverse events, six in the acyclovir group (in
2Wo 300 3so three patients), four in the isoprinosine group
(in two patients) and one in the placebo group.
follow-up for all patients in These were invariably mild, self-limiting, and
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Figure 2 Time to lst recurrent episode during follow-up for all patients in the study.
Clinical laboratory evaluations
The majority of patients did not suffer abi
mal biochemical or haematological chan
The few detected abnormal values were g
erally lower than the expected values, tl
were mild, sporadic, did not follow a partic
pattern and usually returned to normal.
Discussion
The results of this study are similar to thos
previous placebo controlled trials3 wi
have confirmed the efficacy of acyclovii
suppressing recurrent genital herpes. Isopr
sine (Immunovir), an immunomodulator %
low toxicity, has in some studies been show
reduce the severity and speed of resolutioi
mucocutaneous herpes simplex react
tions.'2-17 Although it has been claimec
reduce the duration of viral shedding and t
to healing in patients with primary gei
herpes, a recent comparative study sho
that acyclovir treated patients had a she
duration of symptoms and viral shedding,
healed more quickly than those treated
isoprinosine.` However, neither prepara
appeared to have any effect on the time to
recurrence or the frequency of subseqi
recurrences.
The efficacy of a high dose isoprino
regimen (1 g four times daily) has also E
compared with acyclovir 800 mg daily for
suppression of frequently recurring ger
herpes.`9 In this trial, 100% of patients rec
ing isoprinosine experienced recurrences c
pared with only 36% of those receiving acy
vir experienced recurrences during treatmo
The results of the present study, usin
lower comparative dose of isoprinosine,
similar. Acyclovir treated patients experien
a significantly lower mean number of repo.
recurrences during treatment and significa
longer mean times to first recurrence as c
pared to those receiving isoprinosine or
cebo. When breakthrough recurrences du
treatment occurred, acyclovir treated pati
had a significantly shorter mean duratior
clinically diagnosed lesions than those tre.
with isoprinosine. Thus, treatment with;
clovir was markedly superior to treatment i
isoprinosine which did not show any dem
strable advantages over placebo treatment.
treatments were well tolerated with no
dence of clinically significant effects on haema-
tological and biochemical parameters.
The Kaplan-Meier curves for time to first
recurrence in the post-treatment period were
not significantly different among treatment
groups. However, a significantly higher pro-
portion of patients who had received acyclovir
suffered recurrences during follow up com-
pared with those treated with placebo but not
isoprinosine. Whilst the number of recurrences
in the acyclovir treatment group during follow
up was greater than in the placebo treatment
group, the frequency of recurrences in the
30 placebo group decreased from the observation
to the treatment period, and again from the
treatment to the follow up period. This lower
than expected rate in the placebo group in both
the treatment and follow up periods (perhaps
nor- due to small patient numbers and/or too short
iges. an observation period), confounds the results
gen- somewhat. Nevertheless, recent results (Baten-
hese horst et al, personal communication) have
ular suggested that in patients receiving oral acyclo-
vir for suppression of recurrent genital herpes
infection for periods of 4 years, when treat-
ment is terminated, the time to first recurrence
is considerably longer than for patients who
,e of received shorter courses of therapy.
hich The results of this study demonstrate that
r in acyclovir therapy is substantially more effective
ino- than isoprinosine therapy for the suppression
with of recurrent genital herpes. Similar results
,n to indicating the superiority of acyclovir for sup-
n of pression of recurrent attacks have now been
tiva- shown for studies of both low (1 g) and high
1 to (4 g) daily doses of isoprinosine. Acyclovir is
time clearly the treatment of choice for the manage-
nital ment of patients with both first episode and
wed recurrent genital herpes. In the latter, the
rter choice between episodic treatment with self-
and initiated short treatment courses of oral acyclo-
with vir`` or topical 5% acyclovir cream,23 24
tion (both of which are of proven clinical efficacy)
first and continuous oral suppression, will depend
aent upon individual patient assessment not only of
their frequency of episodes but also the other
Isine physical, psychological and social effects of
)een their recurrent disease.
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